Minghua Shan

24.2k total citations · 2 hit papers
39 papers, 6.0k citations indexed

About

Minghua Shan is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Minghua Shan has authored 39 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 14 papers in Radiology, Nuclear Medicine and Imaging and 13 papers in Oncology. Recurrent topics in Minghua Shan's work include Radiopharmaceutical Chemistry and Applications (13 papers), Prostate Cancer Treatment and Research (11 papers) and Renal cell carcinoma treatment (8 papers). Minghua Shan is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (13 papers), Prostate Cancer Treatment and Research (11 papers) and Renal cell carcinoma treatment (8 papers). Minghua Shan collaborates with scholars based in United States, United Kingdom and France. Minghua Shan's co-authors include Ronald M. Bukowski, Bernard Escudier, Walter M. Stadler, Cezary Szczylik, Tim Eisen, Stéphane Oudard, Tomasz Demkow, Frédéric Rolland, Martin Gore and Apurva A. Desai and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Minghua Shan

38 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

2007 3.8k citations Bernard Escudier, Tim Eisen et al. New England Journal of Medicine profile →
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Minghua Shan

Since Specialization

Citations

This map shows the geographic impact of Minghua Shan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minghua Shan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minghua Shan more than expected).

Fields of papers citing papers by Minghua Shan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minghua Shan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minghua Shan. The network helps show where Minghua Shan may publish in the future.

Co-authorship network of co-authors of Minghua Shan

This figure shows the co-authorship network connecting the top 25 collaborators of Minghua Shan. A scholar is included among the top collaborators of Minghua Shan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minghua Shan. Minghua Shan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	VGG19 and Inception V3 Performance Evaluation for Early Leukemia Detection from Blood Smears 2024 ·Minghua Shan, (unknown), (unknown), (unknown)	0
2	Circulating Tumor Cell-Based Molecular Biomarkers of 177Lu-PSMA-617 Treatment Efficacy in Metastatic Prostate Cancer 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Yasumasa Miyazawa, Arda Könik, (unknown), (unknown), Eugene H. Chung, (unknown), John Kelly, Minghua Shan, Kehui Xu, (unknown), Xianshu Gao, (unknown), Amy M. J. O’Shea, Pedram Heidari, (unknown), Nina Chevalier, Margaret A. Miller, Linda T. Nieman, Thomas S.C. Ng, (unknown)	2
3	Correlation between overall survival (OS) and time to progression (TTP) and between OS and response rate (RR) by RECIST in advanced hepatocellular carcinoma (HCC) 2017 ·Annals of Oncology ·Liping Huang, Yoriko De Sanctis, Minghua Shan, Jordi Bruix, Josep M. Llovet, Ann‐Lii Cheng, Gudrun Meinhardt, Keiko Nakajima	1
4	An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 2017 ·Annals of Oncology ·Oliver Sartor, Robert E. Coleman, Sten Nilsson, Daniel Heinrich, Svein Inge Helle, Joe M. O’Sullivan, Nicholas J. Vogelzang, Øyvind S. Bruland, (unknown), S M Wilhelm, (unknown), Minghua Shan, Michael W. Kattan, Chris Parker	126
5	Weak correlation of overall survival and time to progression in advanced hepatocellular carcinoma. 2017 ·Journal of Clinical Oncology ·Liping Huang, Yoriko De Sanctis, Minghua Shan, Jordi Bruix, Josep M. Llovet, Ann‐Lii Cheng, Gerold Meinhardt, Keiko Nakajima	8
6	Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study 2016 ·Annals of Oncology ·Sten Nilsson, Paul Cislo, Oliver Sartor, Nicholas J. Vogelzang, Robert E. Coleman, Joe M. O’Sullivan, Jonathan Reuning‐Scherer, Minghua Shan, (unknown), Chris Parker	132
7	A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma 2013 ·Gynecologic Oncology ·Thomas J. Herzog, Giovanni Scambia, Byoung‐Gie Kim, Catherine Lhommé, Janina Markowska, Isabelle Ray‐Coquard, Jalid Sehouli, Nicoletta Colombo, Minghua Shan, Oana Petrenciuc, Amit M. Oza	69
8	Radium-223 Dichloride (Ra-223) Impact on Skeletal-Related Events, External Beam Radiation Therapy (EBRT), and Pain in Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastases: Updated Results From the Phase 3 ALSYMPCA Trial 2013 ·International Journal of Radiation OncologyBiologyPhysics ·Jeff M. Michalski, Oliver Sartor, Chris Parker, Minghua Shan, J. Garcia‐Vargas, A. Aksnes, Nicholas J. Vogelzang	3
9	A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial 2013 ·Trials ·José Baselga, Frederico Costa, Henry Gómez, Clifford A. Hudis, Bernardo L. Rapoport, Henri Roché, Lee S. Schwartzberg, Oana Petrenciuc, Minghua Shan, William J. Gradishar	31
10	Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA). 2013 ·Journal of Clinical Oncology ·Nicholas J. Vogelzang, Chris Parker, Sten Nilsson, Robert E. Coleman, C. Gillies O'Bryan-Tear, Minghua Shan, Oliver Sartor	8
11	Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA). 2012 ·Journal of Clinical Oncology ·Oliver Sartor, Daniel Heinrich, Joe M. O’Sullivan, Sophie D. Fosså, Aleš Chodacki, Paweł Wiechno, John Logue, (unknown), Anders Widmark, Dag Clement Johannessen, Sten Nilsson, Peter Hoskin, David Bottomley, Robert E. Coleman, Nicholas J. Vogelzang, C. Gillies O'Bryan-Tear, J. Garcia‐Vargas, Minghua Shan, Chris Parker	12
12	Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). 2012 ·Journal of Clinical Oncology ·Chris Parker, Sten Nilsson, Daniel Heinrich, Joe M. O’Sullivan, Sophie D. Fosså, Aleš Chodacki, Paweł Wiechno, John Logue, (unknown), Anders Widmark, Dag Clement Johannessen, Peter Hoskin, David Bottomley, Robert E. Coleman, Nicholas J. Vogelzang, C. Gillies O'Bryan-Tear, J. Garcia‐Vargas, Minghua Shan, Oliver Sartor	61
13	Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial breakdown → 2009 ·Journal of Clinical Oncology ·Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Staehler, Sylvie Négrier, Christine Chevreau, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sibyl Anderson, (unknown), Minghua Shan, Carol Peña, Chetan Lathia, Ronald M. Bukowski	864
14	6519 Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): collective results from the phase III sorafenib HCC assessment randomized protocol (SHARP) and Asia-Pacific (AP) trials 2009 ·European Journal of Cancer Supplements ·Josep M. Llovet, Ashley Cheng, Shukui Qin, Minghua Shan, Andrea Nadel, K. Burock, Alejandro Forner, Jingwen Zou, Jordi Bruix	2
15	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial 2008 ·Journal of Clinical Oncology ·Jean‐Luc Raoul, Armando Santoro, Michel Beaugrand, Jorge A. Marrero, M. Moscovici, Minghua Shan, Andrea Nadel, D. Voliotis, Jordi Bruix, Josep M. Llovet	15
16	Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma breakdown → 2007 ·New England Journal of Medicine ·Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Négrier, Christine Chevreau, E Solska, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sara M. Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M. Bukowski	3804
17	3507 ORAL Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma 2007 ·European Journal of Cancer Supplements ·Josep M. Llovet, Vincenzo Mazzaferro, Serena Ricci, P Hilgard, Jean‐Luc Raoul, Stefan Zeuzem, Minghua Shan, M. Moscovici, D. Voliotis	24
18	Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival 2006 ·Journal of Clinical Oncology ·Timothy Eisen, Ronald M. Bukowski, Michael Staehler, Cezary Szczylik, Stéphane Oudard, Walter M. Stadler, Brian Schwartz, Ronit Simantov, Minghua Shan, Bernard Escudier	51
19	Novel mutations in the CYP4V2 gene associated with Bietti crystalline corneoretinal dystrophy. 2005 ·PubMed ·Minghua Shan, Bing Dong, (unknown), (unknown), Genlin Li, Yongsheng Yang, Yang Li	44
20	Temporal Quantification of Alzheimer's Disease Severity: 'Time Index' Model 1995 ·Dementia and Geriatric Cognitive Disorders ·J. Wesson Ashford, Minghua Shan, (unknown), Arcot Rajasekar, Frederick A. Schmitt	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact